Thursday

Supreme Court to decide patent dispute over Copaxone

Read how Teva's rivals Mylan Inc., Momenta Pharmaceuticals Inc. and Sandoz, Inc., will be able to start selling generic versions of the drug later this year, after the remaining patents on the drug expire.
Click here to read more